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Palliative Radiation for Lung Cancer Metastases to the
Breast: Two Case Reports
Andreas Rimner, MD, and Kenneth E. Rosenzweig, MD
Metastases from non-small cell lung cancer to the breast represent
an unusual diagnosis. We present two cases of metastatic lung
cancer to the breast that were treated with palliative radiation with
achievement of good local control and symptom relief. We suggest
the use of palliative radiation therapy as an effective and simple
treatment modality for metastatic disease to the breast.
(J Thorac Oncol. 2007;2: 1133–1135)
Breast metastases from non-breast primary tumors are arare finding. They represent approximately 0.5% to 1.3%
of all clinically diagnosed breast tumors. Autopsy series have
found a slightly higher incidence (1.7-6.6%) of metastases to
the breast. Distant metastases from extramammary primary
tumors to the breast are most commonly derived in descend-
ing order from malignant melanomas, lymphomas, lung can-
cer, ovarian carcinoma, soft tissue sarcoma, gastrointestinal
and genitourinary tumors.1 To date, fewer than 500 cases with
metastases to the breast have been reported in the literature.
Of these, approximately 80 patients had a primary tumor
originating in the lung.2
Typically, non-small cell lung cancer (NSCLC) spreads
to the brain, skeletal bone, liver, and adrenal glands. In
approximately 21% of patients, metastatic disease is found at
presentation.3 Rarely does NSCLC metastasize to the skin or
breast. Although mammograms or computed tomographic
(CT) scans can provide some information for distinguishing
primary breast cancer from metastatic disease, pathological
examination using fine-needle aspiration is essential for the
correct diagnosis of metastases to the breast.4
We present two patients who were found to have
biopsy-proven lung metastases to the breast. Both women
were treated with a course of palliative radiation therapy (RT)
using two different fractionation schemes with good local
control and symptom relief.
CASE 1
A 49-year-old woman presented to a local emergency
room with acute onset of altered mental status, dyslexia, and
a 3-week history of severe left frontal and temporal head-
aches. Work-up revealed multiple brain lesions on CT and a
right upper lobe (RUL) mass on chest radiograph.
The patient underwent a subtotal excision of a left
temporal lesion, which was found to be positive for CAM 5.2,
chromogranin, and synaptophysin, consistent with meta-
static high-grade neuroendocrine carcinoma of the large-
cell type. No immunohistochemical staining for ER, PR or
TTF-1 was performed because the lesion was most consistent
with a primary lung tumor. The patient was treated postop-
eratively with whole-brain RT to a total dose of 3750 cGy in
15 fractions using Cobalt-60. She tolerated the treatment
well, and her neurological symptoms resolved shortly after
surgical intervention.
The patient was then started on six cycles of chemo-
therapy with cisplatin (75 mg/m2) and vinorelbine (30 mg/m2).
At 6 months after initial presentation, she developed left
breast mastitis in the superior outer quadrant, which was
initially treated with dicloxacillin. Physical examination
was significant for tenderness on palpation in the superior
outer quadrant of the left breast and a mass measuring
approximately 6  5  4 cm without any palpable axillary
lymphadenopathy. A CT scan of the chest confirmed a new
indistinct nodularity involving the left breast with new left-
sided axillary lymphadenopathy, as well as a slight increase
in the previously noted RUL mass and a new hepatic
nodule (Fig. 1).
Biopsy confirmed metastatic lung cancer to the pa-
tient’s left breast, histologically similar to the left temporal
lobe lesion. She was treated with palliative RT to the left
breast via a tangent technique and received a total dose of
4000 cGy in 20 fractions using 6 MV photons. The patient
tolerated the treatment well and reported decreased pain in
her breast toward the end of treatment. The patient main-
tained good local control of the left-sided breast mass until
her death from progressive metastatic disease 7 months after
breast irradiation.
CASE 2
An 81-year old woman presented with a large left-sided
pleural effusion. Analysis of the pleural fluid revealed ma-
lignant cells consistent with adenocarcinoma. A CT scan of
the chest confirmed a left hilar mass extending to the anterior
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chest wall with pleural thickening and left hilar and axillary
lymphadenopathy. The patient was started on 150 mg erlo-
tinib daily as single-agent therapy and had stable disease for
7 months, at which time the patient noted asymmetry and
nipple retraction in her left breast.
On physical examination, a painless, hard left breast
mass measuring approximately 6 cm was palpable. Neither
inflammatory changes of the skin nor nipple discharge were
noted. Bilateral mammograms of the breasts showed multiple
masses in the medial and lateral left breast, measuring up to
4.0  1.2  1.9 cm in size (Fig. 2), as well as enlarged
left-sided axillary lymph nodes. An ultrasound-guided core
needle biopsy revealed invasive, poorly differentiated adeno-
carcinoma consistent with a pulmonary origin, as it was
positive for TTF-1 and negative for ER, PR, and HER2/NEU.
The patient was treated in the prone position with a
palliative course of radiation to the whole breast and under-
lying chest wall via tangent fields. A total dose of 3975 cGy
was delivered in 15 fractions. The patient tolerated the treat-
ment well without excessive skin toxicity, inflammatory
changes, or other radiation-related complications. On follow-
up, her left breast mass had improved significantly 3 months
after radiation. The patient, however, was noted to have
increased pleural-based thickening, carcinomatosis, and a left
upper lobe mass.
DISCUSSION
The standard of care for metastatic lung cancer remains
chemotherapy, most commonly cisplatin/carboplatin, tax-
anes, gemcitabine, and vinorelbine. For patients with meta-
static disease to the breast, surgical management with mas-
tectomy and lumpectomy has been described.5,6 Although
surgical excision may be a reasonable treatment option for
metastases from radio-resistant primary tumors, such as mel-
anomas and carcinoid tumors, or in the absence of any other
systemic disease,7 RT should be considered as a less invasive
palliative treatment modality for metastases to the breast.
Because there is no established standard fractionation for
palliative breast RT, we chose to give 20 fractions of 200 cGy
each in the first case and 15 fractions of 265 cGy each in the
second case. Both regimens achieved good local control and
symptom relief. We hesitated to give the second patient a
higher dose per fraction (e.g., 300 cGy) because of con-
cerns of excessive skin toxicity, as her tumor was in a
rather superficial location. For that patient, we used the
prone position technique,8 which allowed us to achieve
higher dose homogeneity and to treat only minimal vol-
umes of lungs and heart.
Mean survival for patients with breast metastases has
been described as 10.9 to 12.9 months after diagnosis.9,10 Our
first patient died 8 months after her diagnosis of breast
metastasis. The second patient is alive 6 months after com-
pletion of her radiation.
CONCLUSION
We treated two patients with metastatic lung carcinoma
to the breast with palliative radiation with good local control.
Given the non-invasive nature of treatment delivery and good
morbidity profile of a palliative radiation course, we encour-
age the use of radiation as a palliative modality for metastases
to the breast.
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FIGURE 1. Case 1. Computed tomographic scan of the
chest. A left-sided breast mass and right upper lobe lesion
are seen.
FIGURE 2. Case 2. Mammogram reveals a left-sided breast
mass measuring 4.0  1.2  1.9 cm and nipple retraction.
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